Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | XBP1 | P17861 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474703 | 1.00 | MAPT (0.55) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2884097 | 1.00 | MAPT (0.55) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2879006 | 0.87 | MAPT (0.67) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL13377982 | 0.87 | MAPT (0.67) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2879004 | 0.87 | MAPT (0.67) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL13377966 | 0.87 | MAPT (0.52) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL8340686 | 0.87 | SMN1; SMN2 (0.57) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2881652 | 0.87 | SMN1; SMN2 (0.57) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2881655 | 0.87 | SMN1; SMN2 (0.57) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL2881553 | 0.86 | ALDH1A1 (0.54) | MAPTALDH1A1GAALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1537081-B1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1537081-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020412-A1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | MAPT 4350/4885ALDH1A1 400/4885GAA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.